...
首页> 外文期刊>International Journal of Radiation Oncology, Biology, Physics >Comparison between CT-based volumetric calculations and ICRU reference-point estimates of radiation doses delivered to bladder and rectum during intracavitary radiotherapy for cervical cancer.
【24h】

Comparison between CT-based volumetric calculations and ICRU reference-point estimates of radiation doses delivered to bladder and rectum during intracavitary radiotherapy for cervical cancer.

机译:宫颈癌腔内放疗期间基于CT的体积计算与ICRU参考点估计的辐射剂量向膀胱和直肠的比较。

获取原文
获取原文并翻译 | 示例
           

摘要

Purpose: To compare CT-based volumetric calculations and International Commission on Radiation Units and Measurements (ICRU) reference-point estimates of radiation doses to the bladder and rectum in patients with carcinoma of the uterine cervix treated with definitive low-dose-rate intracavitary radiotherapy (ICRT). Methods and Materials: Between November 2001 and March 2003, 60 patients were prospectively enrolled in a pilot study of ICRT with CT-based dosimetry. Most patients underwent two ICRT insertions. After insertion of an afterloading ICRT applicator, intraoperative orthogonal films were obtained to ensure proper positioning of the system and to facilitate subsequent planning. Treatments were prescribed using standard two-dimensional dosimetry and planning. Patients also underwent helical CT of the pelvis for three-dimensional reconstruction of the radiation dose distributions. The systems were loaded with (137)Cs sources using the Selectron remote afterloading system according to institutionalpractice for low-dose-rate brachytherapy. Three-dimensional dose distributions were generated using the Varian BrachyVision treatment planning system. The rectum was contoured from the bottom of the ischial tuberosities to the sigmoid flexure. The entire bladder was contoured. The minimal doses delivered to the 2 cm(3) of bladder and rectum receiving the highest dose (D(BV2) and D(RV2), respectively) were determined from dose-volume histograms, and these estimates were compared with two-dimensionally derived estimates of the doses to the corresponding ICRU reference points. Results: A total of 118 unique intracavitary insertions were performed, and 93 were evaluated and the subject of this analysis. For the rectum, the estimated doses to the ICRU reference point did not differ significantly from the D(RV2) (p = 0.561); the mean (+/- standard deviation) difference was 21 cGy (+/- 344 cGy). The median volume of the rectum that received at least the ICRU reference-point dose was 2.1 cm(3). In 66 (71%) of 93 cases, <5 cm(3) was treated to this dose. However, for the bladder, the estimated doses to the ICRU reference point were significantly lower than the D(BV2) (p <0.001); the mean difference was 680 cGy (+/- 543 cGy). The median volume of the bladder that received at least the ICRU reference-point dose was 13.0 cm(3). Conclusions: Our data suggest that the estimated dose to the ICRU rectal point may be a reasonable surrogate for the D(RV2). However, this result may not be applicable to other treatment guidelines and ICRT applicator systems. In contrast, the dose to the ICRU bladder point does not appear to be a reasonable surrogate for the D(BV2). Correlation with late complications are needed to define the role of three-dimensional dosimetry in treatment planning.
机译:目的:为了比较采用确定的低剂量率腔内放疗治疗的宫颈癌患者对膀胱和直肠放射剂量的基于CT的体积计算和国际放射单位和测量委员会(ICRU)参考点估计值(ICRT)。方法和材料:2001年11月至2003年3月,前瞻性研究纳入了60例ICRT与CT剂量法的初步研究。大多数患者接受了两次ICRT插入。插入后负荷ICRT施加器后,获得术中正交胶片以确保系统正确定位并便于后续计划。使用标准的二维剂量法和计划来规定治疗方案。患者还接受了骨盆螺旋CT扫描,以三维重建辐射剂量分布。根据低剂量率近距离放射治疗的医疗实践,使用Selectron远程后装系统向系统加载(137)Cs源。使用Varian BrachyVision治疗计划系统生成三维剂量分布。直肠从坐骨结节的底部到乙状结肠弯曲。整个膀胱的轮廓。根据剂量-体积直方图确定输送到2 cm(3)的接受最大剂量的膀胱和直肠的最小剂量(分别为D(BV2)和D(RV2)),并将这些估计值与二维推导进行比较估计到相应ICRU参考点的剂量。结果:总共进行了118次独特的腔内插入,并评估了93次,并以此分析为对象。对于直肠,到ICRU参考点的估计剂量与D(RV2)并无显着差异(p = 0.561);平均(+/-标准偏差)差异为21 cGy(+/- 344 cGy)。至少接受ICRU参考点剂量的直肠中位体积为2.1 cm(3)。 93例患者中有66例(71%)接受了该剂量的<5 cm(3)治疗。但是,对于膀胱,到ICRU参考点的估计剂量显着低于D(BV2)(p <0.001);平均差异为680 cGy(+/- 543 cGy)。至少接受ICRU参考点剂量的膀胱中位体积为13.0 cm(3)。结论:我们的数据表明,估计的ICRU直肠点剂量可能是D(RV2)的合理替代。但是,此结果可能不适用于其他治疗指南和ICRT涂药器系统。相反,ICRU膀胱点的剂量似乎不是D(BV2)的合理替代。需要与晚期并发症相关联以定义三维剂量测定在治疗计划中的作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号